What we could see if the RBL Brilacidin's tests with Corionavirus human respiratory epithelial cells trial are positive is a whole series of good news. IMO you would not want to sell half your holdings on the first run up.

IPIX is so completely under valued that we should see a fundamental rise in the valuation for the whole platform especially Brilacidin for IBD,OM as well as Kevetrin.

Some examples of possible good news which could occur within a few months after a positive test at RBL for Brilacidin.

1. Clinical trial as a single agent
2. Clinical trial in combination with 2 or more drugs
3. Clinical trial for compassionate use in high risk and severely ill Covid 19 patients
4. License for regional use eg Europe, China, Africa,S America, Asia
5. Partnership with large pharmaceutical companies
6. Partnership with University to develop Vaccine or drug
7. Clinical trials for other Corona viruses; SARS and MERS
8. Clinical trials for other enveloped viruses eg influenza
9. Grants and special financing
10. Up listing to a better exchange
11. New management hires; expanded research
12. Major Locust Walk announcement? buyout


http://www.ipharminc.com/press-release/2020/3...-next-week

http://www.ipharminc.com/press-release/2020/3...s-covid-19

http://www.ipharminc.com/press-release/2020/3...stitutions

http://www.ipharminc.com/press-release/2020/4...r-covid-19

http://www.ipharminc.com/press-release/2020/4...t-covid-19

University of Pittsburg uses a super computer to aid Covid 19 research. This is the same center which used a supercomputer to design Brilacidin

https://www.statnews.com/2020/04/09/coronavir...reatments/

John Hopkins epidemiologists give a thoughtful review of Covid 19 research

https://www.statnews.com/2020/04/10/searching...and-peril/

All JMO

Good luck, Farrell